Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
XY
Denmark
- Ownership
- Private
- Development stage
- Other
01
Overview
XY Therapeutics is developing a first-in-class medical treatment for male infertility based on modulation of the RANKL/RANK/OPG pathway in reproductive organs. Their proprietary asset, delivered as a single injection, has shown in preclinical and early clinical studies (including a randomized trial) to increase sperm production and function in selected infertile men. The company has also developed a biomarker for patient selection, now being advanced as a companion diagnostic. The therapy is currently in a Phase 2a clinical trial and, if successful, would represent a significant breakthrough in a field with very few treatment options.
- Therapeutic areas
- Men's Health
- Modalities
- Protein
- Industry
- Biotech
Beyond the preview
Go deeper on XY.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XY.